Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K, Nagata I
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Gynecol Obstet Invest. 1999;47(1):52-7. doi: 10.1159/000010062.
This study was designed to evaluate the clinical significance of the use of preoperative serum tumor markers in primary epithelial ovarian cancer. Subjects comprised 111 patients with primary epithelial ovarian cancer. Lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), carcinoembryonic antigen (CEA), CA19-9, tissue polypeptide antigen (TPA), CA125 and sialyl TN (STN) serum levels were measured within 7 days before surgery. The tumor marker values were compared with the histopathologic diagnosis. The overall agreement between the test results and the actual outcome was calculated using Student's t test and analysis of variance (ANOVA). Survival curves were constructed according to the Kaplan-Meier method, and differences in survival were assessed with the log-rank test. The prognostic significance of tumor markers for survival was assessed in a multivariate analysis with the Cox proportional hazards model. Of the tumor markers examined in this study, CA125 showed the highest positive rate (77.6%), followed by 63.2% for STN and 55.9% for CA19-9. When the positive rate was compared according to histologic types, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma showed the highest positive rates for CA125 (94.1%), CA19-9 (76.9%), CA125 (91.7%) and STN (75.0%), respectively. Regarding the distribution of tumor marker levels according to the FIGO stage, LDH, HBDH, TPA and CA125 were correlated with the clinical stage while CEA, CA19-9 and STN did not show any correlation. From analyses of tumor marker levels according to histologic types, all patients with a ratio of CA125 to CEA of >1, 000 had serous cystadenocarcinoma and a ratio of CA125 to CA19-9 of >50 showed serous cystadenocarcinoma or endometrioid adenocarcinoma. On the other hand, all patients with a ratio of LDH or HBDH to CA19-9 of <1.0 had mucinous cystadenocarcinoma or clear cell carcinoma. From univariate analysis, the survival time of patients with elevated CA125, TPA or STN was significantly shorter than that of patients with normal CA125, TPA or STN levels. When the Cox's proportional hazard model was used, we identified age, clinical stage, clear cell carcinoma and serum STN as independent prognostic factors. Serum CA125, TPA or STN may give significant prognostic information in epithelial ovarian carcinoma. It is noteworthy that STN has been identified as an independent prognostic factor and has a high rate of positivity in clear cell carcinoma.
本研究旨在评估术前血清肿瘤标志物在原发性上皮性卵巢癌中的临床意义。研究对象包括111例原发性上皮性卵巢癌患者。在手术前7天内测定乳酸脱氢酶(LDH)、α-羟丁酸脱氢酶(HBDH)、癌胚抗原(CEA)、CA19-9、组织多肽抗原(TPA)、CA125和唾液酸TN(STN)的血清水平。将肿瘤标志物值与组织病理学诊断结果进行比较。使用Student's t检验和方差分析(ANOVA)计算检测结果与实际结果之间的总体一致性。根据Kaplan-Meier方法构建生存曲线,并用对数秩检验评估生存差异。采用Cox比例风险模型进行多因素分析,评估肿瘤标志物对生存的预后意义。在本研究检测的肿瘤标志物中,CA125的阳性率最高(77.6%),其次是STN为63.2%,CA19-9为55.9%。按组织学类型比较阳性率时,浆液性囊腺癌、黏液性囊腺癌、子宫内膜样腺癌和透明细胞癌的CA125阳性率最高(分别为94.1%)、CA19-9(76.9%)、CA125(91.7%)和STN(75.0%)。关于根据国际妇产科联盟(FIGO)分期的肿瘤标志物水平分布,LDH、HBDH、TPA和CA125与临床分期相关,而CEA、CA19-9和STN未显示任何相关性。根据组织学类型分析肿瘤标志物水平,所有CA125与CEA比值>1000的患者均为浆液性囊腺癌,CA125与CA19-9比值>50的患者为浆液性囊腺癌或子宫内膜样腺癌。另一方面,所有LDH或HBDH与CA19-9比值<1.0的患者均为黏液性囊腺癌或透明细胞癌。单因素分析显示,CA125、TPA或STN升高的患者生存时间明显短于CA125、TPA或STN水平正常的患者。使用Cox比例风险模型时,我们确定年龄、临床分期、透明细胞癌和血清STN为独立的预后因素。血清CA125、TPA或STN可能为上皮性卵巢癌提供重要的预后信息。值得注意的是,STN已被确定为独立的预后因素,且在透明细胞癌中的阳性率较高。